Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-12-2007 | Retinal disorders

Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia

Authors: Subrata Mandal, Pradeep Venkatesh, Zahir Abbas, Rajpal Vohra, Satpal Garg

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 12/2007

Abstract

Background

To evaluate the efficacy and safety of intravitreal bevacizumab (Avastin) in the treatment of subretinal neovascularization (SRNV) secondary to type 2A idiopathic juxtafoveal telangiectasia (IJT).

Methods

Intravitreal bevacizumab (1.25 mg/0.05 ml) was injected as primary treatment into six eyes of six patients with SRNV due to IJT in this nonrandomized, interventional case series. The best-corrected visual acuity (BCVA) was measured and the optical coherence tomography (OCT) and fundus fluorescein angiography (FFA) findings were examined before and after treatment. The patients were followed up for 3–6 months.

Results

Pre-injection BCVA measured 20/400 to 20/120 (mean 20/200). After a mean follow-up of 4.2 months, post-injection BCVA measured 20/200 to 20/50 (mean 20/100). At last visit BCVA improved two or more lines in five eyes (83%) and remained the same in one eye (17%). The mean central foveal thickness improved from 263 μm (range, 165 to 393 μm) to 201 μm (range, 126 to 351 μm), representing an average reduction of 62 μm. Only one eye received more than one (2) bevacizumab injections. No significant complications were observed.

Conclusions

In this small series, intravitreal bevacizumab appears to be a safe and effective treatment for SRNV secondary to type 2A IJT.

Gass JD, Oyakawa RT (1982) Idiopathic juxtafoveal retinal telangiectasis. Arch Ophthalmol 100:769–780PubMed

Gass JD, Blodi BA (1993) Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology 100:1536–1546PubMed

Gass JDM (1997) Retinal capillary diseases. In: Stereoscopic atlas of macular diseases, 4th edn. Mosby, St Louis, pp 506–510

Snyers B, Verougstraete C, Postelmans L, Leys A, Hykin P (2004) Photodynamic therapy of subfoveal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol 137:812–819PubMedCrossRef

Engelbrecht NE, Aaberg TM, Sung J, Lewis ML (2002) Neovascular membranes associated with idiopathic juxtafoveolar telangiectasis. Arch Ophthalmol 120:320–324PubMed

Berger AS, McCuen BW II, Brown GC, Brownlow RL Jr (1997) Surgical removal of subfoveal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Retina 17:94–98PubMedCrossRef

Avery RL, Pieramici DJ, Rabena MD et al (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363–372PubMedCrossRef

Bashshur ZF, Bazarbachi A, Schakal A et al (2006) Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142:1–9PubMedCrossRef

Yamamoto I, Rogers AH, Reichel E, Yates P, Duker JS (2007) Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathologic myopia. Br J Ophthalmol 91(2):157–160PubMedCrossRef

10.

Sakaguchi H, Ikuno Y, Gomi F et al (2007) Intravitreal injection of bevacizumab for choroidal neovascularization associated with pathological myopia. Br J Ophthalmol 91(2):161–165CrossRef

11.

Potter MJ, Szabo SM, Chan EY, Morris AH (2002) Photodynamic therapy of a subretinal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol 133:149–151PubMedCrossRef

12.

Shanmugam MP, Agarwal M (2005) RPE atrophy following photodynamic therapy in type 2A idiopathic parafoveal telangiectasis. Indian J Ophthalmol 53:61–63PubMedCrossRef

13.

Smithen LM, Spaide RF (1997) Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis. Retina 17:94–98

14.

Jorge R, Costa RA, Calucci D, Scott IU (2006) Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol, Nov 29 (Epub ahead of print)

Title: Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia
Authors: Subrata Mandal
Pradeep Venkatesh
Zahir Abbas
Rajpal Vohra
Satpal Garg
Publication date: 01-12-2007
Publisher: Springer-Verlag
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 12/2007
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-007-0567-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2007

Acknowledgement to reviewers 2007

Preoperative B-scan ultrasonography of the vitreoretinal interface in phakic patients undergoing rhegmatogenous retinal detachment repair and its prognostic significance

Promotion of neurite outgrowth and protective effect of erythropoietin on the retinal neurons of rats

Influence of callosal transfer on visual cortical evoked response and the implication in the development of a visual prosthesis

Intravitreal bevacizumab as initial treatment for choroidal neovascularization associated with presumed ocular histoplasmosis syndrome

Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells